+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Xeomin Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • PDF Icon

    Report

  • 175 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 6104041
The xeomin market research report is one of a series of new reports that provides xeomin market statistics, including the xeomin industry global market size, regional shares, competitors with the xeomin market share, detailed xeomin market segments, market trends, and opportunities, and any further data you may need to thrive in the xeomin industry. This xeomin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the increasing prevalence of neurological disorders, growing awareness about botulinum toxin products, rising prevalence of chronic conditions, increasing preference for precision medicine, demand for treatments targeting hyperhidrosis. Major trends in the forecast period include advancements in neuromodulator formulations, innovations in delivery methods, new launches focusing on expanded indications in aesthetic and therapeutic applications, and approvals for extended use cases by regulatory bodies, advancements in personalized dosing.

The growing demand for non-invasive aesthetic procedures is expected to drive the growth of the Xeomin market in the future. Non-invasive aesthetic procedures are cosmetic treatments that do not involve surgery, typically requiring little to no recovery time and posing a lower risk. The rising demand for these procedures is attributed to various factors, including the preference for minimal downtime, advancements in aesthetic technologies, and a greater desire for natural-looking outcomes. Xeomin works by relaxing facial muscles to smooth wrinkles, such as frown lines and glabellar lines, offering a non-surgical option with no recovery time. Its purified formulation provides effective, natural results while reducing the risk of resistance. For example, the British Association of Aesthetic Plastic Surgeons reported that in 2022, there were 31,057 cosmetic surgeries in the UK, a significant 102% increase from the previous year. As a result, the increasing demand for non-invasive aesthetic treatments is set to drive the growth of the Xeomin market.

A key trend in the Xeomin market is the approval of the drug by regulatory bodies to expand its use in both therapeutic and aesthetic applications, which will encourage broader adoption among various patient groups. Drug approval is a process where regulatory authorities assess and authorize a new medication for sale, ensuring its safety, effectiveness, and quality based on clinical trial results. In July 2024, Merz Aesthetics, a US-based medical aesthetics company, announced that the U.S. Food and Drug Administration (FDA) had approved Xeomin (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines, including forehead lines, frown lines, and crow's feet. This approval builds on Xeomin's original 2011 approval for treating glabellar lines (frown lines). The product's innovative formulation, which eliminates unnecessary ingredients, aims to minimize adverse immune responses typically seen with other neurotoxin treatments.

In February 2022, Merz Therapeutics, the Germany-based manufacturer of Xeomin, entered into a partnership with Vensica Therapeutics to develop a needle-free delivery method for treating overactive bladder and other urological conditions. This collaboration combines Xeomin botulinum neurotoxin with Vensica’s cutting-edge ultrasound-assisted drug delivery system. Vensica Therapeutics, an Israel-based company specializing in urology therapeutics, is focused on advancing this innovative approach for delivering treatment.

The key company operating in the xeomin market is Merz Pharmaceuticals GmbH.

North America was the largest region in the xeomin market in 2024. The regions covered in xeomin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the xeomin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Xeomin (incobotulinumtoxinA) is a botulinum toxin type A treatment used for both medical and aesthetic purposes. It functions by inhibiting acetylcholine release, which reduces muscle activity and temporarily smoothens wrinkles. In medical applications, it alleviates muscle-related conditions, while in aesthetics, it enhances facial appearance by reducing muscle tension.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Xeomin include chronic migraine, cervical dystonia, blepharospasm, upper limb spasticity, and glabellar lines. Chronic migraine is a neurological condition characterized by headaches occurring on 15 or more days per month, with at least 8 days presenting migraine symptoms over a period of three months. Xeomin is distributed through channels such as hospital pharmacies, retail pharmacies, online platforms, direct sales, and specialty pharmacies, catering to a wide range of users, including adults and geriatric patients.

The xeomin market consists of sales of injectable solutions, vials, pre-filled syringes, and lyophilized powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Xeomin Market Characteristics
3. Xeomin Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Xeomin Market Trends And Strategies5. Xeomin Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
6. Global Xeomin Growth Analysis And Strategic Analysis Framework
6.1. Global Xeomin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Xeomin Market Growth Rate Analysis
6.4. Global Xeomin Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
6.5. Global Xeomin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
6.6. Global Xeomin Total Addressable Market (TAM)
7. Global Xeomin Pricing Analysis & Forecasts
8. Xeomin Market Segmentation
8.1. Global Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Chronic Migraine
  • Cervical Dystonia
  • Blepharospasm
  • Upper Limb Spasticity
  • Glabellar Lines
8.2. Global Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Sales
  • Specialty Pharmacies
8.3. Global Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Adult
  • Geriatric
9. Global Xeomin Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Xeomin Market Regional And Country Analysis
10.1. Global Xeomin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Xeomin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11. Asia-Pacific Xeomin Market
11.1. Asia-Pacific Xeomin Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Xeomin Market
12.1. China Xeomin Market Overview
12.2. China Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Xeomin Market
13.1. India Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Xeomin Market
14.1. Japan Xeomin Market Overview
14.2. Japan Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Xeomin Market
15.1. Australia Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Xeomin Market
16.1. South Korea Xeomin Market Overview
16.2. South Korea Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Xeomin Market
17.1. Western Europe Xeomin Market Overview
17.2. Western Europe Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Xeomin Market
18.1. UK Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19. Germany Xeomin Market
19.1. Germany Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Xeomin Market
20.1. France Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Xeomin Market
21.1. Eastern Europe Xeomin Market Overview
21.2. Eastern Europe Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Xeomin Market
22.1. North America Xeomin Market Overview
22.2. North America Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Xeomin Market
23.1. USA Xeomin Market Overview
23.2. USA Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24. Canada Xeomin Market
24.1. Canada Xeomin Market Overview
24.2. Canada Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Xeomin Market
25.1. South America Xeomin Market Overview
25.2. South America Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Xeomin Market
26.1. Middle East Xeomin Market Overview
26.2. Middle East Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Xeomin Market
27.1. Africa Xeomin Market Overview
27.2. Africa Xeomin Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Xeomin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Xeomin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Xeomin Market Competitive Landscape And Company Profiles
28.1. Xeomin Market Competitive Landscape
28.2. Xeomin Market Company Profiles
28.2.1. Merz Pharmaceuticals GmbH Overview, Products and Services, Strategy and Financial Analysis
29. Global Xeomin Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Xeomin Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Xeomin Market32. Recent Developments In The Xeomin Market
33. Xeomin Market High Potential Countries, Segments and Strategies
33.1 Xeomin Market In 2029 - Countries Offering Most New Opportunities
33.2 Xeomin Market In 2029 - Segments Offering Most New Opportunities
33.3 Xeomin Market In 2029 - Growth Strategies
33.3.1 Market Trend Based Strategies
33.3.2 Competitor Strategies
34. Appendix
34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. About the Analyst
34.6. Copyright And Disclaimer

Executive Summary

Xeomin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on xeomin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for xeomin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The xeomin market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Indication: Chronic Migraine; Cervical Dystonia; Blepharospasm; Upper Limb Spasticity; Glabellar Lines
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Direct Sales; Specialty Pharmacies
3) By End-User: Adult; Geriatric

Key Companies Profiled: Merz Pharmaceuticals GmbH

Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Merz Pharmaceuticals GmbH